As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...

Tofacitinib etocomil ointment 1.0% has proven effective in treating mild-to-moderate atopic dermatitis, achieving significant ...

Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Kymera Therapeutics, Inc. has outlined its key objectives for 2025, emphasizing its strategy to advance a portfolio of oral ...

Cat allergy symptoms range from mild to severe. While most people experience eye, nose, and respiratory-related symptoms, ...

These photos of 11 common bug bites and stings can help you identify what's responsible. Plus, symptoms and expert tips to ...

Leading biopharmaceutical company Pfizer has unveiled Cibinqo and Staquis, two innovative therapies designed to address eczema across its varying stages, now available in Malaysia. The announcement, ...

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial ...